120 related articles for article (PubMed ID: 31836854)
1. Targetability of STAT3-JAK2 fusions: implications for T-cell lymphoproliferative disorders of the gastrointestinal tract.
Hu G; Phillips JL; Dasari S; Jacobs HK; Luchtel RA; Oishi N; Hundal T; Ahmed NH; Satou A; Epstein AL; Bennani NN; Nowakowski GS; Murray JA; Feldman AL
Leukemia; 2020 May; 34(5):1467-1471. PubMed ID: 31836854
[No Abstract] [Full Text] [Related]
2. Recurrent
Sharma A; Oishi N; Boddicker RL; Hu G; Benson HK; Ketterling RP; Greipp PT; Knutson DL; Kloft-Nelson SM; He R; Eckloff BW; Jen J; Nair AA; Davila JI; Dasari S; Lazaridis KN; Bennani NN; Wu TT; Nowakowski GS; Murray JA; Feldman AL
Blood; 2018 May; 131(20):2262-2266. PubMed ID: 29592893
[No Abstract] [Full Text] [Related]
3. On-target JAK2/STAT3 inhibition slows disease progression in orthotopic xenografts of human glioblastoma brain tumor stem cells.
Stechishin OD; Luchman HA; Ruan Y; Blough MD; Nguyen SA; Kelly JJ; Cairncross JG; Weiss S
Neuro Oncol; 2013 Feb; 15(2):198-207. PubMed ID: 23262510
[TBL] [Abstract][Full Text] [Related]
4. Rituximab Decreases Lymphoproliferative Tumor Formation in Hepatopancreaticobiliary and Gastrointestinal Cancer Patient-Derived Xenografts.
Leiting JL; Hernandez MC; Yang L; Bergquist JR; Ivanics T; Graham RP; Truty MJ
Sci Rep; 2019 Apr; 9(1):5901. PubMed ID: 30976061
[TBL] [Abstract][Full Text] [Related]
5. AZ960, a novel Jak2 inhibitor, induces growth arrest and apoptosis in adult T-cell leukemia cells.
Yang J; Ikezoe T; Nishioka C; Furihata M; Yokoyama A
Mol Cancer Ther; 2010 Dec; 9(12):3386-95. PubMed ID: 21159615
[TBL] [Abstract][Full Text] [Related]
6. The novel JAK inhibitor AZD1480 blocks STAT3 and FGFR3 signaling, resulting in suppression of human myeloma cell growth and survival.
Scuto A; Krejci P; Popplewell L; Wu J; Wang Y; Kujawski M; Kowolik C; Xin H; Chen L; Wang Y; Kretzner L; Yu H; Wilcox WR; Yen Y; Forman S; Jove R
Leukemia; 2011 Mar; 25(3):538-50. PubMed ID: 21164517
[TBL] [Abstract][Full Text] [Related]
7. Icaritin suppresses multiple myeloma, by inhibiting IL-6/JAK2/STAT3.
Zhu S; Wang Z; Li Z; Peng H; Luo Y; Deng M; Li R; Dai C; Xu Y; Liu S; Zhang G
Oncotarget; 2015 Apr; 6(12):10460-72. PubMed ID: 25865044
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of the JAK2/STAT3 pathway in ovarian cancer results in the loss of cancer stem cell-like characteristics and a reduced tumor burden.
Abubaker K; Luwor RB; Zhu H; McNally O; Quinn MA; Burns CJ; Thompson EW; Findlay JK; Ahmed N
BMC Cancer; 2014 May; 14():317. PubMed ID: 24886434
[TBL] [Abstract][Full Text] [Related]
9. The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors.
Hedvat M; Huszar D; Herrmann A; Gozgit JM; Schroeder A; Sheehy A; Buettner R; Proia D; Kowolik CM; Xin H; Armstrong B; Bebernitz G; Weng S; Wang L; Ye M; McEachern K; Chen H; Morosini D; Bell K; Alimzhanov M; Ioannidis S; McCoon P; Cao ZA; Yu H; Jove R; Zinda M
Cancer Cell; 2009 Dec; 16(6):487-97. PubMed ID: 19962667
[TBL] [Abstract][Full Text] [Related]
10. Combination of MEK Inhibitor and the JAK2-STAT3 Pathway Inhibition for the Therapy of Colon Cancer.
Jin J; Guo Q; Xie J; Jin D; Zhu Y
Pathol Oncol Res; 2019 Apr; 25(2):769-775. PubMed ID: 30706361
[TBL] [Abstract][Full Text] [Related]
11. Mesenchymal stem cells regulate the proliferation of T cells via the growth-related oncogene/CXC chemokine receptor, CXCR2.
Lee YS; Won KJ; Park SW; Lee HW; Kim B; Kim JH; Kim DK
Cell Immunol; 2012 Sep; 279(1):1-11. PubMed ID: 23023221
[TBL] [Abstract][Full Text] [Related]
12. Activation of JAK2/STAT3 signaling by osteopontin promotes tumor growth in human breast cancer cells.
Behera R; Kumar V; Lohite K; Karnik S; Kundu GC
Carcinogenesis; 2010 Feb; 31(2):192-200. PubMed ID: 19926637
[TBL] [Abstract][Full Text] [Related]
13. Preclinical evaluation of local JAK1 and JAK2 inhibition in cutaneous inflammation.
Fridman JS; Scherle PA; Collins R; Burn T; Neilan CL; Hertel D; Contel N; Haley P; Thomas B; Shi J; Collier P; Rodgers JD; Shepard S; Metcalf B; Hollis G; Newton RC; Yeleswaram S; Friedman SM; Vaddi K
J Invest Dermatol; 2011 Sep; 131(9):1838-44. PubMed ID: 21677670
[TBL] [Abstract][Full Text] [Related]
14. A natural compound derivative P-13 inhibits STAT3 signaling by covalently inhibiting Janus kinase 2.
Huang H; Niu J; Wang F; Hu L; Yu Q
Invest New Drugs; 2019 Jun; 37(3):452-460. PubMed ID: 30073465
[TBL] [Abstract][Full Text] [Related]
15. Physalin A exerts anti-tumor activity in non-small cell lung cancer cell lines by suppressing JAK/STAT3 signaling.
Zhu F; Dai C; Fu Y; Loo JF; Xia D; Gao SP; Ma Z; Chen Z
Oncotarget; 2016 Feb; 7(8):9462-76. PubMed ID: 26843613
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of JAK2/STAT3 signalling induces colorectal cancer cell apoptosis via mitochondrial pathway.
Du W; Hong J; Wang YC; Zhang YJ; Wang P; Su WY; Lin YW; Lu R; Zou WP; Xiong H; Fang JY
J Cell Mol Med; 2012 Aug; 16(8):1878-88. PubMed ID: 22050790
[TBL] [Abstract][Full Text] [Related]
17. Discovery and evaluation of ZT55, a novel highly-selective tyrosine kinase inhibitor of JAK2
Hu M; Xu C; Yang C; Zuo H; Chen C; Zhang D; Shi G; Wang W; Shi J; Zhang T
J Exp Clin Cancer Res; 2019 Feb; 38(1):49. PubMed ID: 30717771
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic inhibition of Jak activity inhibits progression of gastrointestinal tumors in mice.
Stuart E; Buchert M; Putoczki T; Thiem S; Farid R; Elzer J; Huszar D; Waring PM; Phesse TJ; Ernst M
Mol Cancer Ther; 2014 Feb; 13(2):468-74. PubMed ID: 24398427
[TBL] [Abstract][Full Text] [Related]
19. Cancer-Associated Fibroblasts Share Characteristics and Protumorigenic Activity with Mesenchymal Stromal Cells.
Borriello L; Nakata R; Sheard MA; Fernandez GE; Sposto R; Malvar J; Blavier L; Shimada H; Asgharzadeh S; Seeger RC; DeClerck YA
Cancer Res; 2017 Sep; 77(18):5142-5157. PubMed ID: 28687621
[TBL] [Abstract][Full Text] [Related]
20. The Jak2 small molecule inhibitor, G6, reduces the tumorigenic potential of T98G glioblastoma cells in vitro and in vivo.
Baskin R; Park SO; Keserű GM; Bisht KS; Wamsley HL; Sayeski PP
PLoS One; 2014; 9(8):e105568. PubMed ID: 25162558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
